Furthermore, the US Food and Drug Administration (FDA) has approved pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC, and as monotherapy for patients with PD‐L1‐positive disease as first‐line treatment for metastatic or unresectable, recurrent HNSCC. Here, CD274 is linked to head and neck squamous cell carcinoma.